Y-Intercept (HK)’s Anika Therapeutics ANIK Stock Holding History

Y-Intercept (HK)’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-19,188	Closed	-$357K	–	1211
2023 Q3	$357K	Buy	+19,188	New	+$398K	0.03%	690

Other funds holding ANIK

Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Y-Intercept (HK)'s ANIK Position: Q4 2023 in Review

Y-Intercept (HK) sold out of Anika Therapeutics (ANIK) in Q4 2023, closing a stake of 19,188 shares — an estimated $357K sold.

Y-Intercept (HK) first reported a position in ANIK in Q3 2023 and held it in 1 quarter. The position peaked at $357K in Q3 2023. 117 funds tracked by Wall St. Rank hold ANIK as of Q4 2023.

Y-Intercept (HK) reported no remaining Anika Therapeutics position as of Q4 2023 after selling out during the quarter.
Y-Intercept (HK) sold 19,188 Anika Therapeutics shares in Q4 2023, an estimated $357K.
Y-Intercept (HK) first reported a position in Anika Therapeutics in Q3 2023 and held it in 1 quarter.
Y-Intercept (HK)'s Anika Therapeutics position peaked at $357K in Q3 2023.
117 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2023.

Based on Y-Intercept (HK)'s 13F filing for Q4 2023, filed 13 Feb 2024.